TREA

98840849

Follow

Information

  • Trademark
  • 98840849
  • Serial Number
    98840849
  • Filing Date
    November 06, 2024
    11 months ago
  • Transaction Date
    July 26, 2025
    2 months ago
  • Status Date
    July 25, 2025
    2 months ago
  • Location Date
    July 02, 2025
    3 months ago
  • Status Code
    680
  • Current Location
    TMO LAW OFFICE 120
    Employee Name
    O'NEILL, MARY
  • Attorney Name
    Maury M. Tepper, III
    Law Office Assigned Location Code
    N20
  • Owners
Information
Mark Drawing Code
2
Case File Statements
  • DM0000: The mark consists of two overlapping spirals comprised of rectangles; color is not a feature of the mark.
  • GS0051: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways
  • CC0000: Color is not claimed as a feature of the mark.
Case File Event Statements
  • 11/7/2024 - 11 months ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 5/5/2025 - 5 months ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 5/5/2025 - 5 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/7/2025 - 5 months ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/6/2025 - 5 months ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/7/2025 - 5 months ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/7/2025 - 5 months ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/9/2025 - 5 months ago
    9 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 5/9/2025 - 5 months ago
    11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 5/9/2025 - 5 months ago
    10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 5/9/2025 - 5 months ago
    12 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 5/9/2025 - 5 months ago
    8 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 7/2/2025 - 3 months ago
    14 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/25/2025 - 2 months ago
    16 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/2/2025 - 3 months ago
    15 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/2/2025 - 3 months ago
    13 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA